Foresite Capital Makes Important Investment Decisions under the Guidance of Jim Tananbaum

ForeSite Capital is a healthcare equity firm. The company offers growth to emerging leaders in healthcare. The main headquarters of the firm is in San Francisco, and it has a branch in New York.

Recently, Foresite Capital announced that it had formed a partnership with Molly He, Ph.D. Dr. He is the former Illumina senior director and has more than fifteen year’s genomic and pharmaceutical research experience. In this position, Dr. He is responsible for improvement and innovation of the company’s protein reagent. Dr. He studied bachelors in Biochemistry at Nankai University and also has a Ph.D. from the University of California in protein biophysics. Dr. He also served at Pacific Biosciences as the head of protein sciences and was responsible for the development of protein reagent.

Dr. Molly has ten years’ experience working in the pharmaceutical industry. During this period, she focused on molecule drugs and the antibody structural–based design that targets the immune system and cancer. So far, Dr. He has over twenty patent applications in personalized medicine and next generation sequencing and has published on Bloomberg more than twenty papers.

Molly is a respected scientific researcher when it comes to next-generation sequencing, and Jim Tananbaum is thrilled to welcome her to Foresite Capital. According to Jim, she will be resourceful at Foresite because of her good track record of quality leadership. She will be essential for the expansion and diversification of Forsite Capital’s transformational company portfolio. Dr. He has also confirmed that she is excited to join the Foresite Capital dynamic team and is delighted to get an opportunity to grow the sequencing portfolio which is possibly the breakthrough for drug discovery and clinical research.

Jim Tananbaum is the founder and chief executive officer of Foresite Capital. He has invested assets worth $ 1.1 billion under management. Jim Tananbaum went to the medical school of Harvard and founded Geltex that brought into the market two drugs at less than $80 million. He was also the chief executive officer and founder of Theravance.

Jim Tananbaum has more than twenty years’ experience in healthcare investment. He co-founded two leading health care investment practices and two biopharmaceutical companies. Jim Tananbaum is a force to reckon in the healthcare industry.  Check out his full profile on crunchbase.com.

Other Source: https://about.me/jimtananbaum